BMS slams restricted NICE yes for Daklinza
This article was originally published in Scrip
Executive Summary
New draft guidance from NICE, the health technology appraisal institute for England, recommends Bristol-Myers Squibb's HCV pill Daklinza (daclatasvir), but only for just over half of patients eligible for treatment. The company has slammed the institute's decision, claiming that it leaves genotype 3 patients with few treatment options.